ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last941 to 960 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: Death From Any Cause in the Glycemia Trial.391 of 5,128

327 of 5,123

1.2 points

0.3 to 2.2

10,251NCT00000620

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.503 of 5,128

543 of 5,123

-0.8 points

-2.0 to 0.4

10,251NCT00000620

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: serious adverse events137 of 5,128

107 of 5,123

0.6 points

-0.0 to 1.2

10,251NCT00000620

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Vitamins vs Placebo: deaths from any cause1 of 5,087

1 of 5,065

-0.0 points

-0.1 to 0.1

10,152NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Vitamins vs Placebo: serious adverse events108 of 5,087

173 of 5,065

-1.3 points

-1.9 to -0.7

10,152NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One Serious TEAE55 of 5,064

51 of 5,072

0.1 points

-0.3 to 0.5

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With ≥ Severe Solicited Local and Systemic Reactions75 of 5,064

85 of 5,072

-0.2 points

-0.7 to 0.3

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With ≥ Severe Unsolicited TEAEs13 of 5,064

25 of 5,072

-0.2 points

-0.5 to 0.0

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With ≥ Severe Related Unsolicited Reactions4 of 5,064

6 of 5,072

-0.0 points

-0.2 to 0.1

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One New Onset Chronic Diseases (NOCDs)54 of 5,064

41 of 5,072

0.3 points

-0.1 to 0.6

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One Solicited Local and Systemic Reactions2,776 of 5,064

1,723 of 5,072

20.8 points

18.9 to 22.7

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One Immediate Complaint441 of 5,064

377 of 5,072

1.3 points

0.2 to 2.3

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With ≥ Severe Related Solicited Reactions56 of 5,064

62 of 5,072

-0.1 points

-0.5 to 0.3

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs)661 of 5,064

639 of 5,072

0.5 points

-0.8 to 1.8

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One AE Leading to Withdrawal0 of 5,064

5 of 5,072

-0.1 points

-0.2 to -0.0

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With an Occurrence of Death1 of 5,064

2 of 5,072

-0.0 points

-0.1 to 0.1

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: deaths from any cause1 of 5,064

2 of 5,072

-0.0 points

-0.1 to 0.1

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Quadrivalent VLP Vaccine vs Placebo: serious adverse events55 of 5,064

51 of 5,072

0.1 points

-0.3 to 0.5

10,136NCT03301051

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Districts Which Implement Newer DA-BLS Training Program vs Districts Which Keep Traditional BLS Training Program: Number of Participants With Return of Spontaneous Circulation (ROSC)544 of 1,486

3,118 of 8,641

0.5 points

-2.1 to 3.2

10,127NCT02142387

Effects of a New Dispatcher-Assisted Basic Life Support Training Program

Districts Which Implement Newer DA-BLS Training Program vs Districts Which Keep Traditional BLS Training Program: Number of Participants Surviving to Hospital Discharge85 of 1,486

551 of 8,641

-0.7 points

-1.9 to 0.7

10,127NCT02142387

Effects of a New Dispatcher-Assisted Basic Life Support Training Program

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=48

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00000620-30270839",
        "title": "Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: Death From Any Cause in the Glycemia Trial.",
        "summary": "391 of 5128 against 327 of 5123; risk difference 1.2 points, 95% interval 0.3 to 2.2; NCT00000620, Action to Control Cardiovascular Risk in Diabetes (ACCORD)",
        "record": "/library/comparisons/NCT00000620-30270839",
        "nct_id": "NCT00000620",
        "kind": "outcome",
        "participants": 10251,
        "risk_difference": {
          "value": 0.012418262687954332,
          "lower": 0.002534915276932413,
          "upper": 0.022325055495918684
        },
        "group_1": "391 of 5,128",
        "group_2": "327 of 5,123",
        "difference": "1.2 points",
        "interval": "0.3 to 2.2",
        "trial_title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)"
      },
      {
        "id": "NCT00000620-3875dea1",
        "title": "Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.",
        "summary": "503 of 5128 against 543 of 5123; risk difference -0.8 points, 95% interval -2.0 to 0.4; NCT00000620, Action to Control Cardiovascular Risk in Diabetes (ACCORD)",
        "record": "/library/comparisons/NCT00000620-3875dea1",
        "nct_id": "NCT00000620",
        "kind": "outcome",
        "participants": 10251,
        "risk_difference": {
          "value": -0.007903658914266004,
          "lower": -0.019636397863784117,
          "upper": 0.003822394235238504
        },
        "group_1": "503 of 5,128",
        "group_2": "543 of 5,123",
        "difference": "-0.8 points",
        "interval": "-2.0 to 0.4",
        "trial_title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=49",
  "request_id": "dSpC0hJgTaTKf15P"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?